Galectin Therapeutics Inc GALT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:40 PM EDT
2.92quote price arrow down-0.17 (-5.36%)
Volume
65,191
52 week range
1.28 - 4.27
Loading...
  • Open3.09
  • Day High3.10
  • Day Low2.90
  • Prev Close3.08
  • 52 Week High4.27
  • 52 Week High Date04/12/24
  • 52 Week Low1.28
  • 52 Week Low Date06/26/23

Key Stats

  • Market Cap180.449M
  • Shares Out61.90M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.69
  • YTD % Change79.52

KEY STATS

  • Open3.09
  • Day High3.10
  • Day Low2.90
  • Prev Close3.08
  • 52 Week High4.27
  • 52 Week High Date04/12/24
  • 52 Week Low1.28
  • 52 Week Low Date06/26/23
  • Market Cap180.449M
  • Shares Out61.90M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.69
  • YTD % Change79.52

RATIOS/PROFITABILITY

  • EPS (TTM)-0.74
  • P/E (TTM)-3.93
  • Fwd P/E (NTM)-4.42
  • EBITDA (TTM)-38.072M
  • ROE (TTM)-909.03%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-119.09%

EVENTS

  • Earnings Date05/15/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Galectin Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple...
Richard Uihlein
Independent Chairman of the Board
Joel Lewis CPA
President, Chief Executive Officer, Director
Jack Callicutt CPA
Chief Financial Officer
Address
SUITE 240
4960 PEACHTREE INDUSTRIAL BOULEVARD
Norcross, GA
30071
United States

Top Peers

SYMBOLLASTCHG%CHG
ATOS
Atossa Therapeutics Inc
1.54+0.08+5.82%
KOD
Kodiak Sciences Inc
3.88+0.05+1.31%
TRVI
Trevi Therapeutics Inc
2.80+0.07+2.60%
LENZ
LENZ Therapeutics Inc
15.80-0.11-0.66%
INO
Inovio Pharmaceuticals Inc
11.17-0.19-1.67%